A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis

Active, not recruiting

• Conditions: Histiocytosis
• Interventions: Behavioral: Trail Making Test, Parts A & B; Behavioral: Brief Test of Attention; Behavioral: Symbol Span; Behavioral: Controlled Oral Word Association Test; Behavioral: The Hopkins Verbal Learning Test-Revised; Behavioral: Brief Visuospatial Memory Test-Revised; Behavioral: Hospital Anxiety and Depression Scale; Behavioral: McGill Quality of Life Scale; Diagnostic Test: MR Brain Imaging; Diagnostic Test: Resting state functional MRI; Behavioral: Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)

• Registration Number: NCT03127709
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to try to understand how histopcytosis can cause symptoms or problems in the brain. The tests being done in the study will look at memory and thinking as well as brain function via MRI scan.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-04-07
• Study First Submitted: 2017-04-11
• Study First Submitted QC: 2017-04-20
• Study First Posted: 2017-04-25
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-28
• Last Update Posted: 2024-05-29
• Primary Completion: 2025-04
• Study Completion: 2025-04

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

• Age greater than or equal to 18 years.
• Fluency in English
• Diagnosis of a histiocytic disorder as determined, in the opinion of the study PI, by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
• Will undergo Standard of Care MRI.

Read More

Exclusion Criteria

• Known intracranial involvement of histiocytosis (including dura, leptomeninges and brain parenchyma)
• Prior stroke or intracranial hemorrhage
• Other (non-histiocytic) intracranial neoplasm or neurological disorder deemed by the PI or Co-PI to confound neuroimaging studies (e.g., demyelinating disease)
• Existing diagnosis of a psychiatric disorder or untreated mood disturbance
• Existing diagnosis of a neurodegenerative disease, such as Alzheimer's disease
• Chronic or daily excessive alcohol consumption as determined by the PI.
• History of chronic use of corticosteroids, defined as continuous treatment for six months or longer at any time in the past
• History of severe claustrophobia or other contraindications to patient SOC brain MRI
• Prior intravenous cytarabine or cladribine
• Other current or prior treatments (e.g., high-dose chemotherapy for a different cancer) deemed by the PI or Co-PI to confound imaging studies or cognitive performance

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Participants with a histiocytic disorder diagnosis	The Hopkins Verbal Learning Test-Revised	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	Controlled Oral Word Association Test	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	Symbol Span	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	Trail Making Test, Parts A & B	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	Brief Test of Attention	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	Brief Visuospatial Memory Test-Revised	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	Hospital Anxiety and Depression Scale	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	McGill Quality of Life Scale	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	MR Brain Imaging	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Participants with a histiocytic disorder diagnosis	Resting state functional MRI	Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.

Primary Outcome Measures

Name	Time	Method
neurocognitive function	1 year	Neurocognitive tests will yield raw scores that are converted to z-scores, normalized for participant's age, sex and educational level.The proportion of participants demonstrating cognitive impairment (as defined by 2 or more z-scores less than -1.5) will be summarized. Also, the proportion of participants with impairment (z \< -1.5) for each cognitive test will be summarized. In this way the cognitive assessment yields a dichotomous outcome of impaired versus not impaired for each participant but also allow for more granular assessment of impairment in specific cognitive domains.
quality of life	1 year	questionnaires will yield raw scores (total score for HADS and McGill QOL, as well as anxiety and depression subscores for the HADS). QOL scores will be analyzed as raw scores. Cognitive test scores will be transformed into z-sores (based on score distributions from established normative samples with a mean of 0 and standard deviation of 1) to define the presence/severity of cognitive dysfunction. Scores will be normalized for age, sex and education.
comparing of grey matter volume	1 year	In a whole-brain analysis, first, cortical thickness will be compared between participants and controls and regions of statistically significant grey matter loss will be identified. This is done computionally with a whole-brain, vertex-by-vertex approach, as stated above. Also, as stated above (Section 7), statistical significance thresholding is at p\<0.001, correcting for multiple comparisons using the False Discovery Rate (FDR) method and clustering thresholds, methods used in various high-throughput contexts, including MRI analysis.

Trial Locations

Locations (4)

Memorial Sloan Kettering Cancer Center @ Suffolk; 🇺🇸 Commack, New York, United States

Memorial Sloan Kettering Basking Ridge; 🇺🇸 Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Westchester; 🇺🇸 Harrison, New York, United States

Memorial Sloan Kettering Monmouth; 🇺🇸 Middletown, New Jersey, United States